A propensity score and door-based analysis Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to esbl-producing in kidney transplant recipients

Página do item simplificado
dc.creatorBeléngutiérrez-gutiérrez
dc.creatorLaura Corbella
dc.creatorMical Paul
dc.creatorAlejandra m. Natera
dc.creatorMiruna d. David
dc.creatorMiguel Montejo
dc.creatorRanganathan n. Iyer
dc.creatorLigia Camera Pierrotti
dc.creatorEsperanza Merino
dc.creatorSeema Mehta Steinke
dc.creatorMeenakshi m. Rana
dc.creatorElena Pérez-nadales
dc.creatorPatricia Muñoz
dc.creatorAlessandra Mularoni
dc.creatorChristian Van Delden
dc.creatorPaolo Antonio Grossi
dc.creatorElena María Seminari
dc.creatorErika d. Lease
dc.creatorEmmanuel Roilides
dc.creatorJesús Fortún
dc.creatorHande Arslan
dc.creatorSalvador Pérez-galera
dc.creatorJulien Coussement
dc.creatorZeliha Koçak Tufan
dc.creatorBenoit Pilmis
dc.creatorMarco Rizzi
dc.creatorBelén Loeches
dc.creatorBritt Marie Eriksson
dc.creatorEdson Abdala
dc.creatorFabio Soldani
dc.creatorWarren Lowman
dc.creatorWanessa Trindade Clemente
dc.creatorMario Fernández-ruiz
dc.creatorMarta Bodro
dc.creatorMaría Carmen Fariñas
dc.creatorEsra Kazak
dc.creatorLuis Martínez-martínez
dc.creatorJosé María Aguado
dc.creatorJulián Torre-cisneros
dc.creatorÁlvaro Pascual
dc.creatorJesús Rodríguez-baño
dc.creatorJordi Carratalà
dc.creatorIsabel Oriol
dc.creatorElisa Cordero
dc.creatorJosé Antonio Lepe
dc.creatorBan Hock Tan
dc.creatorFiliz Gunseren
dc.date.accessioned2023-07-04T20:24:15Z
dc.date.accessioned2025-09-08T23:19:07Z
dc.date.available2023-07-04T20:24:15Z
dc.date.issued2021-10-18
dc.format.mimetypepdf
dc.identifier.doi10.1128/AAC.01102-21
dc.identifier.issn00664804
dc.identifier.urihttps://hdl.handle.net/1843/55778
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
dc.rightsAcesso Aberto
dc.subjectErtapenem
dc.subjectInfecções Urinárias
dc.subjectUnidades de Terapia Intensiva
dc.subjectSepse
dc.subjectTransplante de Rim
dc.subject.otherErtapenem
dc.subject.otherExtended-spectrum-b-lactamase-producing Enterobacterales
dc.subject.otherESBL-E
dc.subject.otherUrinary tract infection
dc.subject.otherUT
dc.subject.otherBloodstream infection
dc.subject.otherBSI
dc.subject.otherKidney transplantation
dc.titleA propensity score and door-based analysis Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to esbl-producing in kidney transplant recipients
dc.typeArtigo de periódico
local.citation.epage13
local.citation.issue11
local.citation.spage1
local.citation.volume2
local.description.resumoThere are scarce data on the efficacy of ertapenem in the treatment of bac teremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales(ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treat ment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT,NCT02852902). The association between targeted therapy with ertapenem versus merope nem and clinical cure at day 14 (the principal outcome) was studied by logistic regression.Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with merope nem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome.In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages
local.identifier.orcidhttps://orcid.org/0000-0003-0848-3740
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE PROPEDÊUTICA COMPLEMENTAR
local.publisher.initialsUFMG
local.url.externahttps://journals.asm.org/doi/10.1128/AAC.01102-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to esbl-producing in kidney transplant recipients a propensity score and door-based analysis pdfa.pdf
Tamanho:
716.57 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG